- Apr 2, 2009
- 5,171
- 13,288
- 66
Excerpt from article in today's Wall St. Journal
Graphic New Antismoking Ads Launched
Graphic New Antismoking Ads Unveiled - WSJ.com
Section 918 of the FSPTCA at
http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/pdf/PLAW-111publ31.pdf
FDA is sending Congress a report on Monday.
It will be interesting to see how badly FDA's report to Congress misrepresents the testimony provided at the FDA's Dec. 17th public hearing and the written testimony submitted by 5,300 vapers in January.
Graphic New Antismoking Ads Launched
Graphic New Antismoking Ads Unveiled - WSJ.com
The FDA is also scheduled to update Congress by Monday on its efforts to clamp down on smoking, nearly four years after it assumed regulatory control over tobacco. Next month, the FDA also plans to propose oversight rules for products it doesn't currently regulate, which include cigars, electronic cigarettes and pipe tobacco.
Section 918 of the FSPTCA at
http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/pdf/PLAW-111publ31.pdf
FDA is sending Congress a report on Monday.
(b) REPORT ON INNOVATIVE PRODUCTS.
(1) IN GENERAL.Not later than 3 years after the date
of enactment of the Family Smoking Prevention and tobacco
Control Act, the Secretary, after consultation with recognized
scientific, medical, and public health experts (including both
Federal agencies and nongovernmental entities, the Institute
of Medicine of the National Academy of Sciences, and the
Society for Research on Nicotine and Tobacco), shall submit
to the Congress a report that examines how best to regulate,
promote, and encourage the development of innovative products
and treatments (including nicotine-based and non-nicotine-
based products and treatments) to better achieve, in a manner
that best protects and promotes the public health
(A) total abstinence from tobacco use;
(B) reductions in consumption of tobacco; and
(C) reductions in the harm associated with continued
tobacco use.
(2) RECOMMENDATIONS.The report under paragraph (1)
shall include the recommendations of the Secretary on how
the Food and Drug Administration should coordinate and facilitate
the exchange of information on such innovative products
and treatments among relevant offices and centers within the
Administration and within the National Institutes of Health,
the Centers for Disease Control and Prevention, and other
relevant agencies.
It will be interesting to see how badly FDA's report to Congress misrepresents the testimony provided at the FDA's Dec. 17th public hearing and the written testimony submitted by 5,300 vapers in January.